GLP-1 for Recomposition, Not Just Weight Loss

GLP-1 peptides are the biggest story in pharmaceutical medicine of the last five years. Semaglutide and tirzepatide have transformed the treatment of type 2 diabetes and obesity, and the cardiovascular, kidney, and metabolic outcomes data keeps getting stronger. For men researching men’s health optimization, the standard conversation about GLP-1s is framed around weight loss: are you overweight, should you take one, how much weight can you lose.

That framing misses the more interesting use case. For men in the OPTN target audience (generally healthy, in their 30s-50s, already training and eating reasonably well, looking to optimize rather than overhaul), the useful question is not “should I use a GLP-1 for weight loss” but “should I use a low-dose GLP-1 for body recomposition.” The answer is more nuanced and the protocol looks different than the obesity marketing implies.

For the basics on what peptides are, see Peptides: A No-BS Primer. For the regulatory context that affects access, see Peptide Access After the Kennedy HHS Announcement and the peptides wiki.

The evidence base

Before getting into the protocol, it is worth being clear about the strength of the GLP-1 evidence compared to other peptides.

GLP-1 peptides are not in the same evidence category as BPC-157 or CJC-1295. The obesity trials for semaglutide (Wilding et al., NEJM 2021, STEP-1) and tirzepatide (Jastreboff et al., NEJM 2022, SURMOUNT-1) were large, rigorous, and produced clinically meaningful weight loss. The cardiovascular outcomes trials (SELECT for semaglutide, 2023) showed a 20% reduction in major adverse cardiovascular events in high-risk patients. The kidney outcomes trial (FLOW for semaglutide, 2024) showed a 24% reduction in kidney events. The diabetes prevention, liver disease, and addiction literature is growing.

The evidence is as strong as it gets in modern pharmacology. When I discuss GLP-1s, I am not making cautious claims about thin data. I am reporting on a well-characterized drug class with extensive RCT support.

The caveat is that the RCT evidence is largely in obese and diabetic populations. The specific use case of low-dose GLP-1 for body recomposition in lean-ish healthy men is underdeveloped in the literature. That is a real gap. The mechanism suggests the effect should generalize, but the trials have not been run in the population I am describing.

The mechanism and why it matters for recomposition

GLP-1 peptides work through several mechanisms simultaneously. They slow gastric emptying, which extends satiety. They act centrally in the brain to reduce appetite. They improve insulin sensitivity and glucose handling. They have direct effects on fat metabolism and, at higher doses, on metabolic rate.

For men in the recomposition use case, the relevant effects are:

Appetite reduction. Most men in this audience are not starving and not overeating dramatically. They are eating slightly more than they need to and doing it on autopilot. A low-dose GLP-1 reduces the background appetite drive just enough to make a small caloric deficit feel automatic rather than effortful.

Visceral fat mobilization. GLP-1s preferentially mobilize visceral fat, which is the metabolically active and cardiovascularly dangerous fat around the organs. For men carrying 10-20 pounds of visceral fat without looking dramatically overweight, this is the fat that matters most to address.

Improved insulin sensitivity. Independent of weight change, GLP-1s improve insulin sensitivity, which is itself a meaningful metabolic outcome.

Craving reduction. The central nervous system effects of GLP-1s reduce cravings for high-palatability foods specifically. For men who know what to eat but struggle with specific cravings (late-night snacking, sweets, alcohol), this is the effect that tends to feel most noticeable.

The mechanism supports recomposition when paired with adequate protein and resistance training. The mechanism does not support muscle preservation on its own. If you take a GLP-1, eat whatever happens to be available, and skip the gym, you will lose muscle mass alongside fat mass. That is the failure mode the “muscle loss on Ozempic” stories are about.

The recomposition protocol framework

A GLP-1 recomposition protocol for a man in the OPTN target audience looks different from an obesity protocol.

Starting dose is lower. The obesity protocols for semaglutide titrate from 0.25mg weekly up to 2.4mg weekly over months. The recomposition use case usually starts at 0.25mg weekly and holds there or moves up to 0.5mg. Higher doses increase the risk of excessive appetite suppression and GI side effects without adding benefit for the goal.

For tirzepatide, the obesity protocols go up to 15mg weekly. The recomposition use case usually sits at 2.5mg or 5mg weekly.

Duration is different. Obesity protocols are indefinite or until a target weight is reached. Recomposition protocols are often run as defined cycles: 12-16 weeks on, then off, with reassessment and potentially another cycle later. The goal is not to stay on GLP-1 forever. It is to use the metabolic window to lock in body composition changes that hold after the medication stops.

Protein intake is non-negotiable. 1.6-2.2g per kg of body weight per day, minimum. Men who do not hit this target lose lean mass. Men who do hit it preserve lean mass in most studies. If you cannot or will not eat 150+g of protein a day while on a GLP-1 at a caloric deficit, do not start the protocol.

Resistance training is non-negotiable. Twice a week minimum, three or four times a week ideally. Progressive overload on compound lifts. The mechanical stimulus is the other half of the lean mass preservation equation. Cardio alone will not do it.

Caloric deficit is modest. The GLP-1 makes the deficit feel automatic. The goal is to let the deficit be modest (300-500 calories below maintenance, not 1000) so that recovery and training quality are not compromised. Aggressive deficits on top of GLP-1s are the recipe for muscle loss and burnout.

Reassess at the end of the cycle. DEXA or InBody scan at the start and end if you can. Body weight alone does not tell the story. The goal is to lose 8-15 pounds of fat while gaining or holding muscle, which looks different on a scale than it does on a body composition scan.

What this looks like in practice

For a 40-year-old man at 185 pounds and 20% body fat who is already training twice a week and eating reasonably, a recomposition cycle might look like:

• Weeks 1-4: Semaglutide 0.25mg weekly. Protein target 160-170g per day. Training increased to 3x weekly (two upper, one lower). Modest caloric deficit. Sleep and stress held constant.
• Weeks 5-12: Semaglutide 0.5mg weekly if tolerated well. Same protein, same training, same deficit. Reassess body composition at week 8.
• Weeks 13-16: Hold or taper depending on progress. Begin ramping food intake back up in the final two weeks to prepare for off-cycle maintenance.
• Weeks 17+: Off the medication. Continue training and protein intake to hold the new baseline. Reassess after 8-12 weeks of maintenance to see what held.

Expected outcome for a man in this starting point: 8-12 pounds of fat loss, 0-3 pounds of lean mass gain or maintenance, meaningful visceral fat reduction, and a body composition that is measurably different from the starting point and is possible to hold with continued attention to diet and training.

This is not dramatic. It is a modest, targeted intervention with a clear protocol and a defined endpoint. The dramatic GLP-1 transformations in the news are in a different population using a different protocol.

Side effects and tolerability

GLP-1s have a predictable side effect profile dominated by GI symptoms.

Nausea. The most common side effect, usually mild at low doses, usually resolves within 1-2 weeks of a dose increase. More prominent if you eat large meals or high-fat meals.

Constipation or diarrhea. Variable by patient. Usually manageable with hydration and fiber adjustments.

Reduced appetite to the point of under-eating. The risk at higher doses. Monitor your intake carefully in the first few weeks and do not rely on the appetite signal alone. Eat the protein target even when you are not hungry.

Fatigue. Some men report fatigue in the first few weeks, usually related to under-eating rather than a direct drug effect.

Loss of muscle if training and protein are not in place. The most consequential failure mode and the main reason this protocol is not recommended for men who are not willing to commit to the lifting and the protein.

Serious side effects are uncommon at the doses used for recomposition. The risk profile is well-characterized from the obesity and diabetes trials at much higher doses, and the recomposition dose is at the low end of that range.

Access in 2026

The access story for compounded GLP-1s is worse than it was in 2024. For most of 2022-2024, semaglutide and tirzepatide were on the FDA drug shortage list, which provided the legal basis for 503A compounding. Patients could access compounded versions at $200-400 per month through compounding pharmacies.

Starting in late 2024 and into 2025, the shortage status was removed for tirzepatide and then semaglutide. The legal basis for 503A compounding narrowed significantly. By 2026, the compounded GLP-1 pipeline is a smaller fraction of what it was, and many patients have moved back to brand-name prescriptions.

The brand-name path is expensive. Ozempic, Wegovy, Mounjaro, and Zepbound run $900-1,300 per month at retail. Insurance coverage is spotty and depends on whether you have a diabetes diagnosis, a high BMI, or other qualifying criteria. For most men in the recomposition use case, insurance will not cover it, and the out-of-pocket brand-name cost is the real number to plan around.

Some compounded GLP-1 access persists through specific legal pathways, and the situation continues to evolve. The compounding wiki tracks the current state. For any specific decision today, confirm the access path with your provider before committing to a protocol.

The honest framing

GLP-1s are the most interesting pharmaceutical development in men’s health metabolism in decades. The evidence is strong, the mechanism is well-characterized, and the effects are real. For men who are already doing the fundamentals and are looking for a targeted recomposition intervention, a low-dose, time-limited GLP-1 cycle can produce body composition changes that are otherwise hard to achieve.

This is not a universal recommendation. Most men should fix their sleep, training consistency, and protein intake before adding any medication, including this one. Men who have not done the foundational work will not get the recomposition outcome from a GLP-1, and the protocol is not a substitute for the lifestyle work.

For the men who have done the foundation, understand the tradeoffs, and have a provider willing to work with them on a modest protocol, the recomposition use case is one of the more useful applications of the category. The access question is real and shifting. The physiology is settled. The protocol works when it is paired with the boring things that make any body composition intervention work.

The rest is timing and willingness to do the work.